CMPX - Company ID 0001738021
Compass Therapeutics, Inc. trades as CMPX. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$66.49M. This page tracks Compass Therapeutics, Inc. through 347 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Insider trade (amended) | 4/A | 2026-04-30 |
| Insider trade (amended) | 4/A | 2026-04-30 |
| Insider trade | 4 | 2026-04-29 |
| Insider trade | 4 | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
The largest companies sharing Compass Therapeutics, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Compass Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Compass Therapeutics, Inc. reported a net loss of $66.49M.